Cargando…
A protocol to develop clinical guidelines for inclusion‐body myositis
INTRODUCTION: Inclusion‐body myositis (IBM) is a late‐onset idiopathic inflammatory myopathy associated with selective and progressive muscle weakness and atrophy. Current clinical management of IBM is largely supportive due to its uncertain etiology and lack of effective treatment. Establishing a c...
Autores principales: | Jones, Katherine L., Sejersen, Thomas, Amato, Anthony A., Hilton‐Jones, David, Schmidt, Jens, Wallace, Amanda C., Badrising, Umesh A., Rose, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067551/ https://www.ncbi.nlm.nih.gov/pubmed/26800092 http://dx.doi.org/10.1002/mus.25036 |
Ejemplares similares
-
Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009) -
The heart in sporadic inclusion body myositis: a study in 51 patients
por: Cox, Fieke M., et al.
Publicado: (2009) -
Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017) -
17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018) -
Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)